Advances in diagnosing mitral valve disease in dogs using blood tests

Mitral valve disease is cardiovascular pathology most common in dogs, with a higher prevalence in small dogs and marked age-related incidence: up to 85% of dogs have valvular lesions by age 13 years.

Thus, myxomatous mitral valve disease (MMVD) represents common heart disease in dogsacquired and progressive. Availability heart murmur and current cardiac biomarkers are useful in cases of MMVD but are not discriminatory enough to stage an individual patient.

Thus, study Recently published results provided a preliminary assessment of expression profiles in canine serum and plasma. 15 microRNA markers selected to accurately differentiate between patients with MMVD and healthy controls. In addition, the investigators sought to evaluate the effectiveness of this method in differentiating patients with preclinical (stage B1/B2) and clinical (stage C/D) MMVD.

123 dogs belonging to clients were recruited for the study. After excluding from the sample (n=26), healthy controls (n=50) and MMVD cases (n=47).

The study involved a multicenter, cross-sectional, and prospective study. Thus, researchers compared microRNA expression profiles between dogsand these profiles were used as input for predictive modeling. “This approach aimed to distinguish between healthy controls and patients with MMVD, and to achieve more accurate differentiation between patients with preclinical and clinical MMVD,” they recall.

Regarding the results, the performance indicators showed convincing capabilities of the method. to distinguish healthy controls from dogs with MMVD (sensitivity 0.85, specificity 0.82 and accuracy 0.83). For discrimination between preclinical cases (n= 29) and clinical (n= 18) from the Ministry of Internal Affairs, the results were promising

(sensitivity 0.61, specificity 0.79 and accuracy 0.73).

“The use of microRNA expression profiles in combination with personalized probabilistic predictive models shows good opportunity to develop a reliable diagnostic tool this allows us to distinguish healthy individuals from cases of MMVD (stages B1–D),” the researchers conclude.

In addition, they emphasize that research on the ability differentiate between preclinical and clinical cases MMVD using the same method yielded promising initial results, which could be improved with data from a larger study group.

PROTECTING THE HEART OF DOGS

As the researchers emphasize in their study, myxomatous mitral valve disease is heart disease common in dogs. It is on the occasion of celebrating this Halloweenfrom Hifarmax remembered how Omnicardio Plus This helps protect the hearts of dogs and cats.

Omnicardio Plus is a Hifarmax product from heart support

this helps improve treatment improve the quality of life of cardiac patients. In fact, in cases of cardiovascular animals with amino acid (L-carnitine or taurine) deficiency, this is an important support related to the treatment plan.

Thus, it consists of hawthorn, astaxanthin, L-carnitine, taurine, vitamin E and magnesium and can be used in all heart patients to support myocardial function, support coronary function, stabilize systemic blood pressure and improve myocardial nutrition.